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Huntington's diseaseThe accumulation of misfolded proteins in insoluble aggregates within the neuronal cytoplasm is one of the
common pathological hallmarks of most adult-onset human neurodegenerative diseases. The clearance of
these misfolded proteins may represent a promising therapeutic strategy in these diseases. The two main
routes for intracellular protein degradation are the ubiquitin–proteasome and the autophagy–lysosome
pathways. In this review, we will focus on the autophagic pathway, by providing some examples of how
impairment at different steps in this degradation pathway is related to different neurodegenerative diseases.
We will also consider that upregulating autophagy may be useful in the treatment of some of these diseases.
Finally, we discuss how antioxidants, which have been considered to be beneﬁcial in neurodegenerative
diseases, can block autophagy, thus potentially compromising their therapeutic potential.binsztein).
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(Macro)autophagy involves the formation of double membrane-
bound structures called autophagosomes around portions of cyto-
plasm and associated organelles. These autophagosomes ultimatelyfuse with lysosomes, where their contents are degraded (Yang and
Klionsky, 2010). Autophagy acts as a starvation response to maintain
cellular nutrient levels and helps to regulate intracellular organelle
homeostasis. Autophagy also plays an essential role in the removal of
toxic/aggregate proteins and damaged organelles, like mitochondria,
that would otherwise damage cells during stress.
Mammalian autophagy can be considered in initiation, elongation,
maturation and fusion steps (Fig. 1). Initiation involves the formation
Fig. 1. Impairment of different steps of the autophagic pathway in various neurodegenerative diseases. PD, Parkinson's disease; FTD3, frontotemporal dementia linked to
chromosome 3; ALS, amyotrophic lateral sclerosis; LSDs, lysosomal storage disorders; FAD, early-onset familial Alzheimer's disease.
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This is followed by the elongation phase, where the phagophore
accumulates additional membrane and expands to enclose a region of
cytoplasm, forming an autophagosome. The origins of the membranes
during initiation and elongation are still not fully understood, and
there may be multiple sources (Hamasaki and Yoshimori, 2010).
Membrane could be generated de novo or from existing compart-
ments such as ER (Hayashi-Nishino et al., 2009; Yla-Anttila et al.,
2009), mitochondria (Hailey et al., 2010), and the plasma membrane
(Ravikumar et al., 2010). Autophagosomes then undergo maturation,
which involves recruitment of proteins, microtubule-dependent
transport towards the perinuclear region of the cell, and fusion with
endosomes to form amphisomes. Finally, autophagosomes/amphi-
somes and their contents fuse with lysosomes to form autophagoly-
sosomes (also called autolysosomes) (Jahreiss et al., 2008;
Mizushima, 2007; Orsi et al., 2010; Ravikumar et al., 2009).
Autophagy signalling
Autophagosome formation is regulated by many signals that fall
into two broad categories: mammalian target of rapamycin (mTOR)-
dependent and mTOR-independent.
mTOR-dependent signalling
The mTOR complex integrates a number of signals that monitor
the energy status of cells and negatively regulates autophagosome
biogenesis. mTOR can form two types of functional complex. mTOR
complex (mTORC) 1 is involved in autophagy, but also regulates other
processes like translation and ribosome biogenesis (Jung et al., 2010;
Noda and Ohsumi, 1998; Sarbassov et al., 2005).
Cells can monitor and respond to impaired nutrients or energy
via a number of mechanisms, including essential amino acid
detection via Rag (Sancak et al., 2010, 2008) and activation of
AMP-activated protein kinase (AMPK) in response to elevated AMP
to ATP ratios (Meijer and Codogno, 2006). Both of these pathways
decrease mTOR activity in response to depleted nutrients. Insulin
and growth factor signals also feed in to the mTOR pathway via
insulin receptors, which ultimately signal to activate mTORC1
(Klionsky and Emr, 2000).mTORC1 controls autophagy by direct interaction with the Ulk1-
Atg13-FIP200 complex. Inhibition of mTOR activates Atg13 kinase
activity, leading to phosphorylation of ULK1/2 and FIP200, which in
turn induces autophagy (Chan et al., 2009; Hosokawa et al., 2009;
Jung et al., 2009).
mTOR-independent signalling
There are a number of mTOR-independent signals that signal to
the autophagy pathway. Reduction of free inositol and myoinositol-1,
4, 5-trisphosphate (IP3) levels results in an upregulation of autophagy
(Sarkar et al., 2005). The inositol pathway has been shown to be
regulated by cyclic AMP (cAMP), where increasing adenylyl cyclase
activity results in more intracellular cAMP. This activates phosopho-
lipase Cε (PLCε) through Epac and Rap2B. PLCε produces IP3, which, in
turn, releases calcium from ER stores. Intracytosolic calcium activates
calpains which activate Gsα and that results in increased adenylyl
cyclase activity and increasing cAMP, completing the potential cycle.
How exactly intracytosolic calcium, cAMP and IP3 control autophagy
is unclear (Williams et al., 2008).
PI3P
Beclin-1 is a key regulator of autophagy pathways through its
ability to form a number of different complexes. When bound to Bcl2
family member proteins, Beclin-1 is unable to interact with other
components of autophagy stimulatory complexes. The Bcl-2 interac-
tion is regulated by nutrient status. In response to starvation,
increased JNK1 phosphorylation of Bcl2 disrupts Beclin-1-Bcl2
binding (Wei et al., 2008). In contrast, when incorporated into the
class III PI3-K complex, which comprises Vps34, Vps15 and Atg14,
Beclin-1 is stimulatory and targets to pre-autophagosome structures.
Moreover, Beclin-1 can also become part of a complex that replaces
Atg14with Vps38 and this targets the complex to endosomes andmay
play a role in autophagosome maturation (Cao and Klionsky, 2007).
Rab5, known for its role in conferring membrane identity to early
endosomes and for recruiting effector proteins required for their
maturation into Rab7-positive late endosomes, has also been shown
to interact with and activate Vps34 leading to generation of
phosphatidylinositol 3-phosphate (PI3P) (Christoforidis et al., 1999;
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autophagosome formation (Ravikumar et al., 2008). The class III PI3-K
complex produces PI3P, which is required for recruitment of effector
proteins and leads to phagophore membrane elongation and
autophagosome maturation by enhancing the ubiquitin-like conjuga-
tion of Atg12 to Atg5. A second ubiquitin-like conjugation pathway
involving microtubule protein 1 light chain 3 (MAP1-LC3/LC3/Atg8)
results in the modiﬁcation of LC3-I to LC3-II and its recruitment from
the cytoplasm to autophagosomes. LC3 can mediate membrane
tethering and hemifusion, which may be required for elongation
and maturation of a phagophore into an autophagosome (Nakato-
gawa et al., 2007).
Maturation and fusion
Autophagosomes can form anywhere in the cytoplasm and can
then move bidirectionally along microtubules with a bias towards the
microtubule organising centre, where they are more likely to
encounter lysosomes (Jahreiss et al., 2008; Kimura et al., 2008).
Autophagosome maturation and fusion is dependent on microtubules
and dynein motor protein function (Kochl et al., 2006; Ravikumar et
al., 2005; Webb et al., 2004). Autophagosomes fuse with endosomes
and lysosomes which deliver more components, including lysosomal
hydrolases, which are critical for protein and lipid degradation. These
fusion reactions are dependent on the function of a number of
proteins also known to be important in endosome–lysosome fusion
reactions. ESCRT (endosomal sorting complex required for transport)
proteins are required for correct fusion between autophagosomes and
endosomes/lysosomes, although the mechanisms are unclear. It may
be that they are required for recruitment of fusion machinery, such as
Rab7 and SNAREs to endosome membranes (Filimonenko et al., 2007;
Lee et al., 2007; Rusten et al., 2007; Urwin et al., 2010). SNAREs are
involved in membrane tethering and fusion events and certain
SNARES are important for autophagosome–lysosome fusion (Atlas-
hkin et al., 2003; Furuta et al., 2010). Rab7 is a small GTPase that
recruits a number of effectors that are required for fusion (Gutierrez et
al., 2004; Jager et al., 2004), since loss of function of many Rab7
effectors leads to an accumulation of autophagosomes. Related to this,
defects in lysosome acidiﬁcation by genetic or drug treatments also
prevent autophagosome clearance (Ramachandran et al., 2009).
Autophagy malfunction and neurodegenerative diseases
Genetic studies using mice have highlighted the importance of
constitutive autophagy in post-mitotic cells such as neurons (Hara et
al., 2006; Komatsu et al., 2006), where it has a role removing
aggregate-prone proteins that are toxic for the cell (Levine and
Kroemer, 2009). Mice deﬁcient for neuronal Atg5 or Atg7 (both key
autophagic genes) develop progressive deﬁcits in motor function that
are accompanied by an accumulation of cytoplasmic inclusion bodies
in neurons. It is important to stress that autophagy is clearing normal,
soluble proteins in these situations. These results demonstrate that
constitutive autophagy is important in neurons and that clearance of
diffuse cytosolic proteins through basal autophagy prevents the
accumulation of abnormal proteins, which may disrupt neural
function (Hara et al., 2006; Komatsu et al., 2006). Here, we review
how the impairment of different steps of the autophagic pathwaymay
contribute to different neurodegenerative diseases.
Initiation of autophagosome formation
Beclin-1 levels have been reported to decrease in an age-
dependent way in human brains (Shibata et al., 2006), and this may
lead to a decreased autophagic activity which could explain the effect
of aging in neurodegeneration caused by aggregate accumulation.
Affected brain regions of patients with Alzheimer's disease (AD) showreduced levels of Beclin-1 (Pickford et al., 2008). Heterozygous
deletion of Beclin-1 in a mouse model of AD increased β-amyloid
accumulation and neurodegeneration (Pickford et al., 2008).
Another key regulator of autophagy is the mammalian target of
rapamycin (mTOR) kinase, which suppresses autophagy when it is
activated (Levine and Klionsky, 2004). An abnormal activation of
mTOR has been recently described in a mouse model of Lafora disease
(LD) and in human tissue from patients suffering this neurodegen-
erative disorder (Aguado et al., 2010). LD is a progressive myoclonus
epilepsy, characterized by the accumulation of polyglucosan inclusion
bodies called Lafora bodies (Lafora and Glueck, 1911; Yokoi et al.,
1975). The major genetic defect causing LD is the loss of function of a
protein phosphatase called laforin (Minassian et al., 1998). Lack of
laforin inhibits autophagy, associated with decreased autophagosome
formation, decreased clearance of long-lived proteins, and accumu-
lation of ubiquitinated proteins (Aguado et al., 2010).
Recently, we linked autophagy compromise to Parkinsons' disease
(PD). PD is characterized by the accumulation of α-synuclein in
aggregates. α-Synuclein accumulation is sufﬁcient to cause PD, as this
disease is seen in people with extra copies of the wild-type α-
synuclein gene (Ross et al., 2008). We found that α-synuclein inhibits
autophagosome formation in cell culture and in vivo (Winslow et al.,
2010). This can account for many of the diverse cellular phenotypes
seen in this disease, including intracytoplasmic protein accumulation,
mitochondrial dysfunction and increased apoptosis. Since sporadic PD
is also associated with α-synuclein accumulation, our data may have
much wider implications.
Cargo recognition
Autophagy has long been considered a non-selective bulk
degradation pathway, but there is now evidence suggesting the
existence of selective autophagy, which leads to degradation of
speciﬁc organelles, proteins and pathogens (Kirkin et al., 2009; Kraft
et al., 2009). p62, an ubiquitin-LC3-binding protein, is one of the
molecules that links the cargo, protein aggregates or organelles, to the
vesicle-forming machinery (Kim et al., 2008; Pankiv et al., 2007).
Recently, a defect in cargo recognition mediated by p62 has been
described in different cell models of Huntington's disease (HD)
(Martinez-Vicente et al., 2010). HD is caused by an abnormally
expanded polyglutamine tract close to the N-terminal end of the
huntingtin protein. The mutated protein accumulates in aggregates
within the cell, causing cell death (Imarisio et al., 2008). The mutant
huntingtin can interact with p62, impairing its ability to recognize
cargo aggregates and organelles. For this reason, though the synthesis
of autophagosomes and their fusion to lysosomes is normal, their
cargo content is decreased. This leads to an accumulation of aggregates
and organelles like lipid droplets and mitochondria, which may
contribute to neurodegeneration (Martinez-Vicente et al., 2010).
Autophagosome–lysosome fusion
Dysfunction of ESCRT-III, either by depletion of its essential
subunit mSnf7-2, or by expression of a mutant CHMP2B protein
(another component of the complex) is associated with frontotem-
poral dementia linked to chromosome 3 (FTD3) and amyotrophic
lateral sclerosis (ALS), both characterized by progressive neuronal
accumulation of ubiquitin-positive protein aggregates (Parkinson et
al., 2006; Skibinski et al., 2005). Studies in mature cortical neurons
showed that depletion of ESCRT-III causes autophagosome accumu-
lation and the inhibition of autophagic clearance of cytosolic proteins,
protein aggregates and organelles (Filimonenko et al., 2007; Lee et al.,
2007; Rusten et al., 2008). Similarly, depletion of ESCRT-I and ESCRT-II
causes an accumulation of autophagosomes, suggesting that the
normal ESCRT function is required for autophagosome–lysosome
fusion (Lee et al., 2007).
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Once the autophagosomes fuse with the lysosomes, their cargo is
degraded by the lysosomal hydrolases. Impairment of the activities of
speciﬁc lysosomal hydrolases leads to the accumulation of the
corresponding substrates inside lysosomes, a feature of most
lysosomal storage disorders (LSDs) (Futerman and van Meer, 2004).
A common cellular pathological feature in these diseases and their
animal models is impaired autophagosome degradation, leading to
the accumulation of autophagosomes and increased levels of LC3-II,
and the accumulation of polyubiquitinated proteins and dysfunctional
mitochondria, which are the putative mediators of cell death
(Settembre et al., 2008). This have been described in different LSDs
such as in Danon disease (Tanaka et al., 2000), GM1 gangliosidosis
(Takamura et al., 2008), neuronal ceroid-lipofuscinoses (NCLs) (Koike
et al., 2005), Pompe disease (Fukuda et al., 2006), multiple sulfatase
deﬁciency (MSD) and mucopolysaccharidosis type IIIA (MPSIIIA)
(Settembre et al., 2008).
Acidiﬁcation of the new formed autolysosomes is needed for
activation of the lysosomal hydrolases and effective proteolysis of
substrates, and it is mediated by a vacuolar [H+] ATPase (v-ATPase)
(Yamamoto et al., 1998). Recently, an impairment has been described
in autolysosomal acidiﬁcation in mouse models and cells from
patients with early-onset familial Alzheimer's disease (FAD) due to
mutations of preselinin-1 (PS1) (Lee et al., 2010), the most common
cause of FAD (Cataldo et al., 2004). PS1 is needed for v-ATPase
targeting to lysosomes, lysosome acidiﬁcation, and proteolysis during
autophagy (Lee et al., 2010).
Consequences of autophagy compromise
There may be various consequences of impaired autophagy that
are relevant for neurodegenerative diseases. For instance, a failure to
clear dysfunctional mitochondrial may lower apoptotic thresholds for
susceptible neurons. In addition, autophagy compromise leads to the
accumulation of the ubiquitin-binding protein p62. Excessive levels of
p62 impair the trafﬁcking of ubiquitinated proteins to the protea-
some, thereby leading to a secondary deﬁciency of the ubiquitin
proteasome system in cells with autophagy compromise (Korolchuk
et al., 2009). This leads to the accumulation of short-lived critical
cellular regulators that are proteasome substrates, like p53, which
cause stress and ultimately apoptosis when their levels are elevated.
Thus, a secondary compromise of the ﬂux of proteasome substrates
may be an important factor regulating toxicity when autophagic
activity is decreased. This study also helps explain why the aggregates
formed when autophagy is compromised are decorated by antibodies
to both ubiquitin and p62. Our data suggest that the p62 forms the
seeds for these aggregates, which, in turn, sequester ubiquitin and
proteins that are ubiquitinated, via the ubiquitin-binding domain of
p62 (Korolchuk et al., 2009).
Candidates for pharmacological induction of autophagy
mTOR-dependent pathway
Chemical induction of autophagy protects cells against the toxic
insults of aggregate-prone proteins associated with neurodegenera-
tion by promoting their clearance. The ﬁrst known drug identiﬁed as
an autophagy inducer is rapamycin, which was already in clinical use
for other indications. In mammalian cells, rapamycin inhibits the
kinase activity of mTOR by forming a complex with the immunophilin
FK506-binding protein of 12 kDa (FKBP12) that binds to and
inactivates mTOR, leading to the upregulation of autophagy (Berger
et al., 2006). Our studies have established that rapamycin treatment
enhances the clearance of mutant huntingtin fragments, reduces
aggregate formation and protects against toxicity in cell, Drosophilaand mouse models of Huntington's disease (HD) (Berger et al., 2006;
Ravikumar et al., 2006; Sarkar et al., 2009;Webb et al., 2003).We have
also shown that rapamycin promotes the clearance of other
intracytoplasmic, disease-associated, aggregate-prone proteins, in-
cluding mutant proteins associated with spinocerebellar ataxias,
mutant forms of α-synuclein implicated in PD, and mutant tau
responsible for FTD, thereby attenuating their toxicity (Berger et al.,
2006; Menzies et al., 2006; Williams et al., 2006). It is likely that
autophagy regulates clearance of SDS-soluble species of these
proteins, and that the formation of large aggregates visible by light
microscopy is inﬂuenced by autophagy clearing the smaller aggregate
precursors (Rubinsztein, 2006). In Drosophila models of these
diseases, the beneﬁts of rapamycin appear to be autophagy depen-
dent, as this drug had no effects on the proteinopathy toxicity in ﬂies
expressing these mutant proteins when the activity of different
autophagy genes was reduced (Berger et al., 2006; Pandey et al., 2007;
Wang et al., 2009). These ﬁndings support the view that the primary
beneﬁts of this drug aremediated by autophagy and not by alternative
mechanisms like disruption of the translational machinery. Consistent
with the Drosophila data, the rapamycin analogue CCI-779 reduces
both mutant huntingtin and ataxin-3 levels, thereby attenuating
toxicity in mouse models of HD and spinocerebellar ataxia type 3,
respectively (Menzies et al., 2010; Ravikumar et al., 2004).
Rapamycin treatment and autophagy upregulation also protects
cells against pro-apoptotic insults that are independent of aggregates,
for example, with staurosporine treatment in cell culture and
paraquat toxicity in Drosophila (Ravikumar et al., 2006). Thus,
rapamycin treatment may be useful in certain disease conditions
(including various neurodegenerative diseases) where a slow but
increased rate of apoptosis is evident, even if they are not associated
with overt aggregate formation.
Recently, the delivery of the Beclin-1 gene was shown to induce
autophagy and reduce amyloid and α-synuclein pathology in mouse
models of AD and Parkinson/Lewy Body diseases, respectively
(Pickford et al., 2008; Spencer et al., 2009). This approach, which is
likely to be downstream or independent of mTOR, provides proof of
principle for autophagy induction as a protective strategy in a wide
range of neurodegenerative diseases.
mTOR-independent autophagy activators
TOR proteins control several cellular processes besides autophagy,
including repression of ribosome biogenesis and protein translation
(Berger et al., 2006; Yang et al., 2005). These processes likely
contribute to the complications seen with its long-term use.
Accordingly, we and others have embarked on a series of studies to
identify novel autophagy-upregulating compounds and have discov-
ered pathways that are independent of the target of rapamycin.
Lithium, a mood stabilising drug used for the long-term treatment of
affective disorders, facilitates the clearance of mutant huntingtin in
HD cell and Drosophila models by reducing IP3 levels, and reduces
mutant protein-associated aggregation and toxicity (Sarkar et al.,
2005). Consistent with the role of IP3 in autophagy, pharmacological
inhibition of the IP3R by xestospongin B also induces autophagy
(Criollo et al., 2007). Additionally, sodium valproate and carbamaze-
pine, which inhibit inositol synthesis and therefore decrease IP3
levels, also reduced the accumulation and aggregation of mutant
huntingtin and its toxicity in HD cell models, and protected against
neurodegeneration in Drosophila models of HD (Sarkar and Rubinsz-
tein, 2008; Williams et al., 2008).
A rational mechanism for combination treatment of mTOR-independent
and mTOR-dependent pathways
Our laboratory investigated the prospect of a combination
treatment strategy that would enable greater upregulation of
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mTOR-dependent and -independent pathways. By using dual treat-
ment with rapamycin and lithium, we demonstrated that autophagy
can be enhanced to a greater extent by the inhibition of both
pathways, compared to saturating doses of drugs that inhibit each
pathway individually (Sarkar et al., 2008). This strategy may allow a
larger safety window before toxic effects from non-autophagy-related
effects of each drug are seen. Proof of principle of this combination
treatment approach in vivo has also been shown in HD ﬂy models
(Sarkar et al., 2008).
The rationale for enhancing autophagy usingmodulators of mTOR-
dependent andmTOR-independent pathways may also be seen by the
use of saturating doses of rapamycin with other mTOR-independent
autophagy inducers.
Screening of compounds—SMERs and various drugs
To explore other novel therapeutic agents capable of modulating
autophagy for the purpose of treating neurodegeneration, a high-
throughput small molecule screen was performed in yeast (Sarkar et
al., 2007). From the 50,729 compounds screened, several small
molecule inhibitors and enhancers (SMERs) of the cytostatic effects
of rapamycin were identiﬁed. Among these, SMERs 10, 18 and 28
increased clearance of autophagy substrates, such as A53T α-
synuclein and mutant huntingtin, and reduced huntingtin toxicity in
the Drosophila HD model (Sarkar et al., 2007). This effect was
independent of mTOR.
A further screen was then performed on a library comprising 253
FDA-approved drugs and pharmacologically active compounds by
analyzing their effects on the clearance of known autophagy
substrates (Williams et al., 2008). The screen revealed various
autophagy enhancers such as L-type Ca2+ channel antagonists (e.g.,
verapamil, loperamide and amiodarone), the K+ATP channel opener
minoxidil, and the Gi-signalling activators clonidine and rilmenidine,
whose mechanisms of action were found to be linked in a potential
cyclical fashion(Williams et al., 2008). These compounds induce
autophagy by acting on the cAMP–Epac–PLCε–IP3-calcium pathway,
described above. Overlapping drugs were also identiﬁed in an
independent screen (Zhang et al., 2007). The drugs decrease mutant
huntingtin aggregate levels via mTOR-independent autophagy and
confer protection against toxicity in HD cell, ﬂy and zebraﬁsh models
(Williams et al., 2008). A follow-up study has shown that rilmenidine
enhances the removal of mutant huntingtin in a transgenic mouse
model and also alleviates toxicity (Rose et al., 2010). This is exciting,
since rilmenidine is a safe, centrally acting antihypertensive drug that
acts on the same receptors to reduce blood pressure as it does to
induce autophagy. These Gi-coupled imidazoline receptors are widely
expressed in the brain. Thus, we believe this drug is a strong candidate
to take forward into clinical trials in HD patients, given its safety and
suitability for long-term use.
Antioxidant drugs and autophagy
The appreciation of the relationships between autophagy and
neurodegeneration has increased dramatically in the last decade.
Many neurodegenerative diseases, like HD, exhibit increased oxida-
tive stress, and antioxidants have been proposed as a rational
therapeutic strategy. Indeed, there are at least 2 major trials of
antioxidants in progress for HD. However, many antioxidant drugs
inhibit autophagy in cells, primary neurons and in mice. By blocking
autophagy, antioxidant drugs can increase the levels of aggregate-
prone proteins associated with neurodegenerative disease, like
mutant huntingtin. In ﬂy models of Huntington's disease, the rescue
seen with rapamycin is abrogated by antioxidant treatment and both
antioxidant drugs and overexpression of superoxide dismutase can
exacerbate the disease phenotype. Furthermore, antioxidants en-hanced mutant huntingtin accumulation in our zebraﬁsh model of HD
(Underwood et al., 2010). Thus, the potential beneﬁts of ROS
scavengers in neurodegenerative diseases, for instance, as buffers
against the toxic effects of increased reactive oxygen species, may be
compromised by their autophagy-blocking properties. These studies
also suggest that autophagy inhibitors may be broadly deleterious in
such neurodegenerative diseases.
Concluding remarks
In conclusion, while our understanding of autophagy continues to
inform about pathogenic mechanisms and provide rational therapeu-
tic strategies for neurodegenerative conditions, further studies on
autophagy may also inform about treatment strategies and physio-
logical processes, which were previously thought to be unrelated to
protein clearance pathways. Clearly, the strategies may need to be
tailored to ﬁt the speciﬁc autophagy defects in particular diseases. For
instance, diseases associated with autophagy impairment due to
increased mTOR activity may be amenable to therapy with mTOR
inhibitors. Additionally, care may be needed before upregulating
autophagy when there is a blockade in autophagosome–lysosome
fusion.
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